These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 28101678

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S, Sarsenov D, Erdogan Z, Ordu C, Celebi F, Nur Pilanci K, Ozturk A, Selamoglu D, Alco G, Aktepe F, Eralp Y, Tuzlali S, Ozmen V.
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [Abstract] [Full Text] [Related]

  • 4. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S, Tanriverdi O, Karapolat I, Demir L, Bayoglu V, Can A, Akyol M, Yilmaz Y, Oktay Tarhan M.
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [Abstract] [Full Text] [Related]

  • 5. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC.
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [Abstract] [Full Text] [Related]

  • 6. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
    Desouki MM, Atta IS, Wolff DJ, Self SE.
    Turk Patoloji Derg; 2016 Oct; 32(3):178-85. PubMed ID: 27562392
    [Abstract] [Full Text] [Related]

  • 7. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L, Cheng L, Zhu X, Gao Y, Fan L, Wang Z.
    BMC Cancer; 2021 Mar 06; 21(1):238. PubMed ID: 33676449
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J, Xia Y, Wu Q, Zhu S, Chen C, Yang W, Wei W, Sun S.
    Oncotarget; 2017 Jul 25; 8(30):49370-49379. PubMed ID: 28472761
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    Yamamura J, Kamigaki S, Fujita J, Osato H, Manabe H, Tanaka Y, Shinzaki W, Hashimoto Y, Komoike Y.
    BMC Cancer; 2021 Apr 29; 21(1):476. PubMed ID: 33926418
    [Abstract] [Full Text] [Related]

  • 11. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
    Karray-Chouayekh S, Trifa F, Khabir A, Sellami-Boudawara T, Frikha M, Gargouri A, Mokdad-Gargouri R.
    Histol Histopathol; 2012 Mar 29; 27(3):377-85. PubMed ID: 22237715
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F, Vogel C, Pahmeyer C, Eichler C, Holtschmidt J, Ratiu D, Mallmann P, Malter W.
    Anticancer Res; 2018 Oct 29; 38(10):6023-6026. PubMed ID: 30275235
    [Abstract] [Full Text] [Related]

  • 18. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
    Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.
    Tumori; 2012 Nov 29; 98(6):743-50. PubMed ID: 23389361
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES, Korean Breast Cancer Society.
    Breast Cancer Res Treat; 2010 Aug 29; 123(1):177-87. PubMed ID: 20574671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.